E Prostanoid 2 (EP2)/EP4-mediated Suppression of Antigen-specific Human T-cell Responses by Prostaglandin E2
Overview
Authors
Affiliations
Prostaglandin E2 (PGE2) is a lipid mediator that displays important immunomodulatory properties, such as polarization of cytokine production by T cells. Recent investigations have revealed that the effect of PGE2 on cytokine production is greatly influenced by external stimuli; however, it is unclear whether PGE2 plays a significant role in major histocompatibility complex-mediated antigen-specific T-cell responses via binding to one of four subtypes of E prostanoid (EP) receptor alone or in combination. In the present study, we sought to determine the effect of PGE2 on antigen-specific CD4+ T-cell responses in humans, especially in terms of receptor specificity. We used purified protein derivative (PPD) and Cry j 1 as T helper type 1 (Th1) and Th2-inducing antigens, respectively. We generated several different Cry j 1- and PPD-specific T-cell lines (TCLs). PGE2 significantly and dose-dependently inhibited the proliferation and subsequent production of interleukin-4 by Cry j 1-specific TCLs and of interferon-gamma by PPD-specific TCLs upon antigen stimulation. Administration of EP2 receptor agonist and EP4 receptor agonist suppressed these responses in an adenylate cyclase-dependent manner, while EP1 and EP3 receptor agonists did not. Messenger RNA for EP2, EP3 and EP4, but not EP1, receptors were detected in Cry j 1- and PPD-specific TCLs, and no differences in EP receptor expression were observed between them. Furthermore, PGE2 and EP2 receptor agonist significantly inhibited interleukin-5 and interferon-gamma production by peripheral blood mononuclear cells in response to Cry j 1 and PPD stimulation, respectively. These results suggest that PGE2 suppresses both Th1- and Th2-polarized antigen-specific human T-cell responses via a cAMP-dependent EP2/EP4-mediated pathway.
Quandt Z, Jacob S, Fadlullah M, Wu C, Wu C, Huppert L BJC Rep. 2024; 2(1):46.
PMID: 39516257 PMC: 11524064. DOI: 10.1038/s44276-024-00057-7.
GPCRs: emerging targets for novel T cell immune checkpoint therapy.
Dickinson K, Yee E, Vigil I, Schulick R, Zhu Y Cancer Immunol Immunother. 2024; 73(12):253.
PMID: 39358616 PMC: 11447192. DOI: 10.1007/s00262-024-03801-7.
Chambers E, Vukmanovic-Stejic M, Shih B, Trahair H, Subramanian P, Devine O Nat Aging. 2023; 1(1):101-113.
PMID: 37118005 DOI: 10.1038/s43587-020-00010-6.
Airway and Systemic Prostaglandin E2 Association with COPD Symptoms and Macrophage Phenotype.
Tejwani V, Villabona-Rueda A, Khare P, Zhang C, Le A, Putcha N Chronic Obstr Pulm Dis. 2023; 10(2):159-169.
PMID: 36976551 PMC: 10392871. DOI: 10.15326/jcopdf.2022.0375.
Harnessing prostaglandin E signaling to ameliorate autoimmunity.
Burkett J, Doran A, Gannon M Trends Immunol. 2023; 44(3):162-171.
PMID: 36707339 PMC: 9975049. DOI: 10.1016/j.it.2023.01.004.